A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Objective The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of ce...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Arthritis & rheumatology (Hoboken, N.J.) Ročník 71; číslo 7; s. 1101 - 1111
Hlavní autoři:	Deodhar, Atul, Gensler, Lianne S., Kay, Jonathan, Maksymowych, Walter P., Haroon, Nigil, Landewé, Robert, Rudwaleit, Martin, Hall, Stephen, Bauer, Lars, Hoepken, Bengt, Peyrecave, Natasha, Kilgallen, Brian, Heijde, Désirée
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 01.07.2019 John Wiley and Sons Inc
Témata:	Active control Adult Ankylosing spondylitis Arthritis C-Reactive Protein - immunology Certolizumab Pegol - therapeutic use Disease control Double-Blind Method Female Humans Immunotherapy Inflammatory diseases Magnetic Resonance Imaging Male Middle Aged Monoclonal antibodies Nonsteroidal anti-inflammatory drugs Original Randomization Remission Rheumatic diseases Sacroiliitis - diagnostic imaging Spondylarthropathies - diagnostic imaging Spondylarthropathies - drug therapy Spondylarthropathies - immunology Spondylitis Spondyloarthritis TNF inhibitors Treatment Outcome Tumor Necrosis Factor Inhibitors - therapeutic use Tumor necrosis factor-α
ISSN:	2326-5191, 2326-5205, 2326-5205
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!